Researchers from the Assistance Publique Hopitaux de Paris have compared the expense of radio-frequency ablation and cryoablation, based on the destruction of one 2- or 3-cm tumor in more than 50 procedures at a Paris hospital. Their findings, presented as a poster at ESGAR 2001, showed both procedures to be more expensive than percutaneous ethanol injection. Costs would fall by 5% to 10% for RF ablation and by 25% to 30% for cryoablation if the annual numbers of each procedure doubled, the researchers said.
Researchers from the Assistance Publique Hopitaux de Paris have compared the expense of radio-frequency ablation and cryoablation, based on the destruction of one 2- or 3-cm tumor in more than 50 procedures at a Paris hospital. Their findings, presented as a poster at ESGAR 2001, showed both procedures to be more expensive than percutaneous ethanol injection. Costs would fall by 5% to 10% for RF ablation and by 25% to 30% for cryoablation if the annual numbers of each procedure doubled, the researchers said.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.